QualityStocksNewsBreaks – CEL-SCI Corporation (NYSE American: CVM) Closes on $7.75M Public Offering
CEL-SCI Corporation (NYSE American: CVM), a phase 3 cancer-immunotherapy company, has closed on its previously announced public offering. The offering was comprised of 3,875,000 shares of common stock, offered at $2 per share, resulting in $7.75 million in gross proceeds before deducting underwriting discounts and offering expenses. According to the announcement, CEL-SCI anticipates using the funds for continued development of Multikine as well as for working capital and general corporate purposes. ThinkEquity acted as sole book-running manager for the offering. To view the full press release, visit https://ibn.fm/kaEhi About CEL-SCI Corporation CEL-SCI believes that boosting a patient’s immune system while it…
